2018
Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States
Giri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Davidoff A, Huntington S. Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States. Blood 2018, 132: 978. DOI: 10.1182/blood-2018-99-119791.Peer-Reviewed Original ResearchSupportive care measuresMultiple myelomaInfluenza vaccinationMM therapySupportive careCare measuresFlu seasonAntiviral prophylaxisComorbidity burdenMedicare beneficiariesPre-existing chronic kidney diseaseContinuous Medicare Parts ANon-Hispanic black ethnicityMultivariable logistic regression modelRacial disparitiesHigher comorbidity burdenLower comorbidity burdenNovel MM therapiesSupportive care therapySupportive care useEnd Results-MedicareTreatment-related toxicityChronic kidney diseaseProportion of patientsYear of diagnosis
2015
Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2015, 126: 3285. DOI: 10.1182/blood.v126.23.3285.3285.Peer-Reviewed Original ResearchHigh-risk myelodysplastic syndromeHR-MDS patientsKaplan-Meier survival curvesEnd of studyHMA initiationMedian OSClinical trialsComorbidity countHazard ratioHigh school educationClinical practiceMultivariate Cox proportional hazards modelSurvival curvesEnd Results-Medicare databaseMedian household incomeRandomized phase III trialReal-world clinical practiceCox proportional hazards modelOlder MDS patientsDisability Status ScoreRetrospective cohort studyOverall survival advantagePhase III trialsYear of diagnosisErythropoiesis-stimulating agents